Clinical Indicators Combined with S100A12/TLR2 Signaling Molecules to Establish a New Scoring Model for Coronary Artery Lesions in Kawasaki Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Oct 12

PMID 37824465

Authors

Yali Wu

Shasha Wang

Yang Zhou

Youjun Yang

Shiyu Li

Wei Yin

Yan Ding

Affiliations

Soon will be listed here.

Abstract

Coronary artery lesions (CALs) are the most common and serious complication of Kawasaki disease (KD), and the pathogenesis is unknown. Exploring KD-specific biomarkers and related risk factors is significant for clinical diagnosis and treatment. This study aimed to explore the feasibility of combining clinical indicators with S100A12/TLR2-associated signaling molecules for the predictive modeling of CALs in KD. A total of 346 patients (224 males and 122 females) with KD who visited the rheumatology department of Wuhan Children's Hospital between April 2022 and March 2025 were enrolled and divided into two groups according to the presence or absence of CALS (292 patients had CALs and 54 patients did not). Forty-one variables were collected from the two groups, including demographic characteristics, clinical manifestations, and laboratory data. Single nucleated cells from each patient were extracted, and the expression of the S100A12/TLR2 signal transduction-related molecules S100A12, TLR2, MYD88, and NF-κB were detected by real-time fluorescent quantitative polymerase chain reaction. Statistically significant variables were subjected to logistic regression analysis to determine the independent risk factors for KD with CALs, and a new risk score model was established to assess the predictive efficacy based on receiver operating characteristic curves. Sixteen variables significantly differed between the no-CALs and CALs groups: gender, fever duration, white blood cells (WBC), hemoglobin (HGB), Ce reactive protein (CRP), procalcitonin, serum ferritin (SF), erythrocyte sedimentation rate (ESR), fibrinogen (FIB), aspartate aminotransferase-to-alanine aminotransferase ratio (AST/ALT), serum albumin (ALB), sodium (Na), Interleukin (IL-10), tumor necrosis factor (TNF-α), S100 calcium binding protein A12 (S100A12), and Myeloid Differentiation Factor 88 (MYD88) (p < 0.05). After performing a univariate analysis, 12 variables (gender, fever duration, WBC, HGB, CRP, SF, ESR, FIB, AST/ALT, ALB, Na, and S100A12) were included in the multifactorial binary logistic regression, which showed that fever duration ≥ 6.5 days, ESR ≥ 46.5 mm/h, AST/ALT ≤ 1.51, and S100A12 ≥ 10.02 were independent risk factors for KD with CALs and were assigned scores of 3, 2, 1, and 2, respectively, according to the odds ratio (OR). The total score of each patient was counted, and a new prediction model for KD combined with CALs was established, where < 3.5 was considered low risk and ≥ 3.5 was regarded as high risk; the sensitivity, specificity, Jorden index, and area under the curve of this scoring system were 0.667, 0.836, 0.502, and 0.838, respectively. This new scoring model has good efficacy for predicting the occurrence of KD with CALs. The expression of S100A12 was significantly increased in the CALs group and was an independent risk factor for the occurrence of CALs, and has the potential as a biomarker for predicting KD with CALs.

References

Wittkowski H, Hirono K, Ichida F, Vogl T, Ye F, Yanlin X . Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum. 2007; 56(12):4174-81. DOI: 10.1002/art.23042. View

Ye F, Foell D, Hirono K, Vogl T, Rui C, Yu X . Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol. 2004; 94(6):840-4. DOI: 10.1016/j.amjcard.2004.05.076. View

Wei D, Li N, Zeng Y, Liu B, Kumthip K, Wang T . The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes. J Biol Chem. 2016; 291(23):12294-309. PMC: 4933277. DOI: 10.1074/jbc.M115.711598. View

Kuo H . Preventing coronary artery lesions in Kawasaki disease. Biomed J. 2017; 40(3):141-146. PMC: 6136281. DOI: 10.1016/j.bj.2017.04.002. View

Kawasaki T, Kosaki F, Okawa S, SHIGEMATSU I, Yanagawa H . A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974; 54(3):271-6. View

Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y . JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease. Circ J. 2020; 84(8):1348-1407. DOI: 10.1253/circj.CJ-19-1094. View

Rosenkranz M, Schulte D, Agle L, Wong M, Zhang W, Ivashkiv L . TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation. 2005; 112(19):2966-73. DOI: 10.1161/CIRCULATIONAHA.105.537530. View

Armaroli G, Verweyen E, Pretzer C, Kessel K, Hirono K, Ichida F . Monocyte-Derived Interleukin-1β As the Driver of S100A12-Induced Sterile Inflammatory Activation of Human Coronary Artery Endothelial Cells: Implications for the Pathogenesis of Kawasaki Disease. Arthritis Rheumatol. 2018; 71(5):792-804. DOI: 10.1002/art.40784. View

Hua W, Ma F, Wang Y, Fu S, Wang W, Xie C . A new scoring system to predict Kawasaki disease with coronary artery lesions. Clin Rheumatol. 2018; 38(4):1099-1107. DOI: 10.1007/s10067-018-4393-7. View

10.

Krishna M, Sundaram B, Dhanalakshmi K . Predictors of coronary artery aneurysms in Kawasaki disease. Clin Pediatr (Phila). 2014; 53(6):561-5. DOI: 10.1177/0009922814530802. View

11.

Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K . Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. J Am Heart Assoc. 2017; 6(7). PMC: 5586277. DOI: 10.1161/JAHA.116.005370. View

12.

Liu B, Forman M, Valsamakis A . Optimization and evaluation of a novel real-time RT-PCR test for detection of parechovirus in cerebrospinal fluid. J Virol Methods. 2019; 272:113690. DOI: 10.1016/j.jviromet.2019.113690. View

13.

Foell D, Wittkowski H, Vogl T, Roth J . S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2006; 81(1):28-37. DOI: 10.1189/jlb.0306170. View

14.

Liu B, Martins T, Peterson L, Hill H . Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review. Cytokine. 2021; 142:155478. PMC: 7901304. DOI: 10.1016/j.cyto.2021.155478. View

15.

. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. Circ J. 2014; 78(10):2521-62. DOI: 10.1253/circj.cj-66-0096. View

16.

Newburger J, Takahashi M, Gerber M, Gewitz M, Tani L, Burns J . Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart.... Circulation. 2004; 110(17):2747-71. DOI: 10.1161/01.CIR.0000145143.19711.78. View

17.

Sakurai Y . Autoimmune Aspects of Kawasaki Disease. J Investig Allergol Clin Immunol. 2018; 29(4):251-261. DOI: 10.18176/jiaci.0300. View

18.

Fu S, Gong F, Xie C, Zhu W, Wang W, Shen H . S100A12 on circulating endothelial cells surface in children with Kawasaki disease. Pediatr Res. 2010; 68(2):165-8. DOI: 10.1203/PDR.0b013e3181e67ce8. View

19.

Hu J, Ren W . Analysis of the Risk Factors in Prognosis of Kawasaki Disease With Coronary Artery Lesions. Front Pediatr. 2021; 9:798148. PMC: 8688820. DOI: 10.3389/fped.2021.798148. View

20.

Huang Y, Li S, Huang L, Chen P, Lin Y, Lin C . Identifying genetic hypomethylation and upregulation of Toll-like receptors in Kawasaki disease. Oncotarget. 2017; 8(7):11249-11258. PMC: 5355262. DOI: 10.18632/oncotarget.14497. View